



Advancing Lung Cancer Trials with Precision

Lung cancer is a core area of expertise for Worldwide Clinical Trials. We support lung cancer programs from early-phase development through global registrational studies across biomarker-defined patient populations, targeted therapies, immunotherapies, antibody-drug conjugates (ADCs), and other emerging treatment approaches.

Successfully executing lung cancer trials requires expertise in biomarker-driven patient identification and enrollment, molecular testing strategies, evolving standards of care, and increasingly complex trial designs across a competitive recruitment landscape. Partnering with an oncology CRO that understands these complexities is critical to accelerating development, generating high-quality data, and supporting study success.

Robust pipeline of lung cancer trials

- **Global footprint**
 - Programs across N.A., E.U., APAC, LATAM and MENA
- **Study experience**
 - 60+ early and late phase studies with 8,200+ patients
 - NSCLC and SCLC
- **Site experience**
 - 455+ investigative sites in 32 countries
- **Next-generation drug modalities**
 - ADCs
 - Multi/bi-specific antibodies
 - Cell therapies/CAR T
 - Inhibitors (checkpoint, kinase, and small molecule)

We understand lung cancer trials

- **Enrollment challenges**
 - Diagnosis at advanced stage
 - Disease stigma e.g., smoking
 - Strict I/E criteria
- **Treatment difficult** due to disease heterogeneity and various subtypes and genetic mutations
- **Targeted therapy treatment varies**
 - Biomarker specific
 - Specific genetic mutation

What Sets Us Apart



Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.



Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.

Additional Differentiators



Flexible solutions
& best-in-class
technologies



Data-centric
approach with
visual analytics
& clinical science



Site relationships
with rapid startup




Global footprint:
4,000+ across NA,
EU, LATAM, MENA
& APAC

Active Next-Gen Oncology Experience


Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase




■ Early Phase ■ Late Phase
■ Observational/LTFU

Indication



■ Solid ■ Heme

Drug Class



■ Targeted Therapy ■ Other
■ Immuno-Oncology



Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

[Contact us](#) to learn how we can support your oncology program from FIH through registration.